Menu
Search
|

Menu

Close
X

Versartis Inc VSAR.OQ (NASDAQ Stock Exchange Global Select Market)

2.03 USD
+0.03 (+1.25%)
As of Jul 20
chart
Previous Close 2.00
Open 2.00
Volume 8,719
3m Avg Volume 89,660
Today’s High 2.03
Today’s Low 2.00
52 Week High 22.10
52 Week Low 1.35
Shares Outstanding (mil) 36.08
Market Capitalization (mil) 73.97
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
40
FY16
0
FY15
0
EPS (USD)
FY18
-0.249
FY17
-3.334
FY16
-3.137
FY15
-2.842
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.05
Price to Sales (TTM)
vs sector
1.85
8.10
Price to Book (MRQ)
vs sector
0.94
4.20
Price to Cash Flow (TTM)
vs sector
--
22.23
Total Debt to Equity (MRQ)
vs sector
9.06
17.32
LT Debt to Equity (MRQ)
vs sector
9.06
13.18
Return on Investment (TTM)
vs sector
-89.11
13.17
Return on Equity (TTM)
vs sector
-95.74
15.10

EXECUTIVE LEADERSHIP

Srinivas Akkaraju
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Jay Shepard
President, Chief Executive Officer, Principal Financial Officer, Director, Since 2017
Salary: $522,173.00
Bonus: --
Shane Ward
Senior Vice President, General Counsel, Since 2017
Salary: --
Bonus: --
Jay Stout
Senior Vice President, Technical Operations, Since 2017
Salary: --
Bonus: --
Kevin Haas
Principal Accounting Officer, Vice President - Finance, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4200 Bohannon Dr Ste 250
MENLO PARK   CA   94025-1021

Phone: +1650.9638580

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop somavaratan for additional growth disorders, such as idiopathic short stature (ISS), small for gestational age (SGA) and Turner Syndrome. Somavaratan is engineered using XTEN technology to extend the residence time in the bloodstream by reducing the clearance of recombinant human growth hormone (rhGH) from the body by the two primary mechanisms, kidney filtration and receptor mediated clearance.

SPONSORED STORIES